“Low-flow” versus “mid-flow” extracorporeal CO2 removal: A review of clinical performance and device efficiency

25 November 2015 White Papers

Analysis of published clinical studies using approved veno-venous ECCO2R devices shows that the Hemolung RAS can provide the same amount of CO2 removal as traditional “mid-flow” ECCO2R devices. (read more)

How ActivMix Technology Enhances CO2 Removal in the Hemolung RAS

16 October 2015 White Papers

By ALung Technologies, Inc. The Hemolung Respiratory Assist System (RAS) is the only extracorporeal CO2 removal system that has been specifically designed to provide the safest, simplest and most efficient ECCO2R therapy. Other systems are non-integrated, modified ECMO or dialysis arrangements, and as such, have neither the level of safety, simplicity, nor efficiency of the (read more)

Intubation and Mechanical Ventilation vs. Partial ECCO2R with the Hemolung RAS: Complications and Invasiveness

8 April 2014 White Papers

By ALung Technologies, Inc. Intubation and mechanical ventilation are the standard method of support for patients suffering from acute respiratory failure. However, the complications associated with intubation and mechanical ventilation are significant and potentially life-threatening. These risks are often not accounted for when considering the risk to benefit profile of using low-flow, partial ECCO2R in (read more)

The Case for Extracorporeal Carbon Dioxide Removal (ECCO2R) in Acute Respiratory Failure

6 March 2014 White Papers

Extracorporeal carbon dioxide removal (ECCO2R) provides carbon dioxide clearance independently of the lungs as an alternative or supplement to mechanical ventilation. In this presentation, the clinical indications and evidence for ECCO2R are reviewed. View the presentation in your browser below, or download the PDF. (read more)

Low-Flow ECCO2R for Acute Exacerbation of COPD

4 March 2014 White Papers

By ALung Technologies, Inc. Chronic obstructive pulmonary disease (COPD) is an irreversible, progressive, lung disease caused by chronic bronchitis and emphysema, resulting in persistent expiratory airflow limitation.1 According to the World Health Organization, COPD is the fourth leading cause of death worldwide, and projected to increase by more than 30% over the next 10 years.2 Acute exacerbations are a major cause of worsened (read more)